Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019
BEDMINSTER, N.J. and DUBLIN, Ireland , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's
View HTML
Toggle Summary Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
BEDMINSTER, N.J. , and DUBLIN, Ireland , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced that new data showing the reduction in total major adverse cardiovascular (i.e., ischemic) events shown in
View HTML
Toggle Summary Amarin Provides Preliminary 2018 Results and 2019 Outlook
U.S. Sales Force Increased to 400 Sales Professionals for 2019 Following Unprecedented Positive Results of Vascepa® Cardiovascular Outcomes Study Presented in November 2018 Unaudited Full-Year 2018 Net Total Revenue Estimated Between $224 and $228 Million , including Fourth Quarter Estimate Between
View HTML
Toggle Summary Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
BEDMINSTER, N.J. , and DUBLIN, Ireland , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $200.0 million , before deducting the
View HTML
Toggle Summary Amarin Announces Proposed Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”).  All of the shares in the proposed offering are to be sold by Amarin.  The offering is
View HTML
Toggle Summary Amarin to Present at the Evercore ISI HealthCONx Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol Management Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks
View HTML
copyright
© 2019, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation